2025
Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.
Machtay M, Torres-Saavedra P, Thorstad W, Nguyen-Tân P, Siu L, Holsinger F, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen S, Gwede C, Dicker A, Yao M, Jordan R, Dorth J, Lee N, Chan J, Dunlap N, Bar-Ad V, Stokes W, Chakravarti A, Sher D, Rao S, Harris J, Yom S, Le Q, Bar-Ad V, Bednarz G, Bowles D, Breen S, Burtness B, Chakravarti A, Chan J, Chung C, Cmelak A, Dicker A, Dorth J, Dunlap N, El-Naggar A, Gwede C, Harris J, Holsinger F, Jones C, Jordan R, Krempl G, Le Q, Lee N, Lominska C, Ma D, Machtay M, Mell L, Nguyen-Tan P, Quon H, Raben A, Rao S, Samuels S, Sher D, Siu L, Spencer S, Stokes W, Takiar V, Thorstad W, Torres-Saavedra P, Wilke C, Yao M, Yom S, Young M. Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer. Journal Of Clinical Oncology 2025, jco2401829. PMID: 39841939, DOI: 10.1200/jco-24-01829.Peer-Reviewed Original ResearchDisease-free survivalOverall survivalToxicity ratesEpidermal growth factor receptor expressionGrowth factor receptor expressionHead and neck cancerHPV-negative diseaseIntermediate-risk cancerIntensity-modulated RTStratified log-rank testAcute toxicity ratesSecondary end pointsOral cavity cancerSquamous cell carcinomaLog-rank testHead and neckLong-term toxicityBenefit of RTFisher's exact testPostoperative RTCell carcinomaReceptor expressionNeck cancerOral cavityRadiotherapy
2024
Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis
Sassano M, Seyyedsalehi M, Kappil E, Zhang S, Zheng T, Boffetta P. Exposure to per- and poly-fluoroalkyl substances and lung, head and neck, and thyroid cancer: A systematic review and meta-analysis. Environmental Research 2024, 266: 120606. PMID: 39672496, DOI: 10.1016/j.envres.2024.120606.Peer-Reviewed Original ResearchPooled relative riskRelative riskHead and neckEstimate pooled relative risksConfidence intervalsExposure to per-Evidence of publication biasNatural log-unit increaseThyroid cancerCase-control studyPolyfluoroalkyl substances exposuresAssociated with lungPublication biasSystematic reviewPositive associationMeasured serum levelsMeta-analysisSerum PFAS levelsTesticular cancerProspective studyAssociationSerum levelsPFAS exposureExposure assessmentLung cancerRadiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation
Beddok A, Orlhac F, Rozenblum L, Calugaru V, Créhange G, Dercle L, Nioche C, Thariat J, Marin T, El Fakhri G, Buvat I. Radiomics-driven personalized radiotherapy for primary and recurrent tumors: A general review with a focus on reirradiation. Cancer/Radiothérapie 2024, 28: 597-602. PMID: 39406602, DOI: 10.1016/j.canrad.2024.09.002.Peer-Reviewed Original ResearchPersonalized radiotherapyTumor localizationTreatment planningMedian AUCImaging modalitiesRisk of recurrenceHead and neckImprove treatment precisionPredicting clinical outcomesOptimal treatment planQuantitative imaging biomarkersRecurrent tumorsApplication of radiomicsRecurrent cancerClinical radiotherapyExternal validationClinical outcomesRadiotherapyReirradiationLack of external validationMEDLINE searchTreatment precisionImaging biomarkersImaging protocolTumorBCAM (basal cell adhesion molecule) protein expression in different tumor populations
Burela S, He M, Trontzas I, Gavrielatou N, Schalper K, Langermann S, Flies D, Rimm D, Aung T. BCAM (basal cell adhesion molecule) protein expression in different tumor populations. Discover Oncology 2024, 15: 381. PMID: 39207605, PMCID: PMC11362396, DOI: 10.1007/s12672-024-01244-1.Peer-Reviewed Original ResearchPD-L1 expressionBasal cell adhesion moleculePD-L1Quantitative immunofluorescenceAssociated with better OSPD-L1 protein expressionCancer typesBladder urothelial tumorsProtein expressionMultiple immune checkpointsHead and neckMultiple tumor typesEvidence of hypermethylationImmune checkpointsImmunotherapy responseCell adhesion moleculesTumor typesValidation cohortTumor populationCancer patientsTumorPredictive valueAdhesion moleculesNovel biomarkersWidespread expressionAbbreviated MRI in the evaluation of dizziness: report turnaround times and impact on length of stay compared to CT, CTA, and conventional MRI
Tu L, Tegtmeyer K, de Oliveira Santo I, Venkatesh A, Forman H, Mahajan A, Melnick E. Abbreviated MRI in the evaluation of dizziness: report turnaround times and impact on length of stay compared to CT, CTA, and conventional MRI. Emergency Radiology 2024, 31: 705-711. PMID: 39034381, DOI: 10.1007/s10140-024-02273-7.Peer-Reviewed Original ResearchLength of stayEvaluation of dizzinessAbbreviated MRIConventional MRIMRI protocolEmergency departmentNon-contrast CT headConventional MRI protocolHead and neckPosterior circulation strokeAnalysis of length of stayTurnaround timeED length of stayCT headNo significant differenceAcute dizzinessCirculation strokeRetrospective analysisDizzinessAcute settingAssociated with greater impactMRI studiesImaging modalitiesMRIPatientsLongitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy
Balázs Z, Balermpas P, Ivanković I, Willmann J, Gitchev T, Bryant A, Guckenberger M, Krauthammer M, Andratschke N. Longitudinal cell-free DNA characterization by low-coverage whole-genome sequencing in patients undergoing high-dose radiotherapy. Radiotherapy And Oncology 2024, 197: 110364. PMID: 38834154, DOI: 10.1016/j.radonc.2024.110364.Peer-Reviewed Original ResearchCopy number alterationsCell-free DNACancer patientsTumor fractionHead and neck cancer patientsPlasma cell-free DNAAssociated with tumor aggressivenessSCCHN patient samplesSystemic tumor spreadTumor-agnostic approachHigh-dose radiotherapyPlasma cfDNA samplesWhole-genome sequencingHead and neckCell-free DNA sequencing dataDetect viral DNAViral DNAOligometastatic patientsSCCHN patientsRadiotherapy guidelinesTumor spreadTumor aggressivenessImaging findingsCfDNA samplesTreatment strategiesThe NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers.
Roof S, Hanna G, Rettig E, Routman D, Holsinger F, Kalman N, Bhatia A, Patel M, Jabalee J, Yom S, Baliga S, Raben A, Sims J, Kaczmar J, Bhayani M, Berger B, Del Vecchio Fitz C. The NAVigate-HPV Registry: A comprehensive biomarker evidence base for HPV-driven cancers. Journal Of Clinical Oncology 2024, 42: e15045-e15045. DOI: 10.1200/jco.2024.42.16_suppl.e15045.Peer-Reviewed Original ResearchHPV-driven cancersHPV-related cancersHuman papillomavirusClinical dataHead and neckClinical outcome dataBlood-based assayPrecision cancer medicineClinical careRoutine clinical careDNA scoreUterine cervixAcademic medical facilityImprove patient outcomesAnal canalClinicopathological featuresEligible subjectsU.S. cancer centersBlood testsOncogenic driversCancer CenterTherapeutic approachesTumor biomarkersPatientsCancer medicineA randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.
Long G, Haddad R, Robert C, Mortier L, Schadendorf D, Uppaluri R, Svane I, Saiag P, Lim A, Soria Rivas A, Scolyer R, Chaney M, Abildgaard C, Ahmad Q, Ringeisen F, McDowell D, Burtness B. A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors. Journal Of Clinical Oncology 2024, 42: tps2701-tps2701. DOI: 10.1200/jco.2024.42.16_suppl.tps2701.Peer-Reviewed Original ResearchEvent-free survivalAdjuvant pembrolizumabNeoadjuvant pembrolizumabCancer vaccinesAdjuvant treatmentCohort CCohort APD-L1-positive cellsRandomized phase 2 trialExpansion of T cellsPost-treatment tumor tissuesPotential anti-tumor activityImmune checkpoint inhibitorsResponse to pembrolizumabLocally advanced diseasePathologic tumor responseTherapeutic cancer vaccinesImmune-suppressive cellsPhase 1/2 trialDisease-free survivalNeo-adjuvant treatmentPhase 2 trialTreatment of multiple tumor typesSquamous cell carcinomaHead and neckDe-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy
Yarbrough W, Schrank T, Burtness B, Issaeva N. De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy. Viruses 2024, 16: 536. PMID: 38675879, PMCID: PMC11053602, DOI: 10.3390/v16040536.Peer-Reviewed Original ResearchConceptsHPV+ HNSCCHPV-associated head and neck cancerHead and neck cancerHuman papillomavirus-associatedDe-escalation therapyDetect recurrent diseaseTreatment of recurrenceHPV-associated cancersHead and neckEarly treatment of recurrencePapillomavirus-associatedDevelopment of biomarkersResponsive tumorsRecurrent diseaseStandard therapyCompanion biomarkersHPV carcinogenesisHPV vaccinationNeck cancerPoor prognosisDecrease morbidityHNSCCEarly treatmentMolecular vulnerabilitiesPersonalized therapyMR-guided stereotactic radiation therapy for head and neck cancers
Wang H, Yang J, Lee A, Phan J, Lim T, Fuller C, Han E, Rhee D, Salzillo T, Zhao Y, Chopra N, Pham M, Castillo P, Sobremonte A, Moreno A, Reddy J, Rosenthal D, Garden A, Wang X. MR-guided stereotactic radiation therapy for head and neck cancers. Clinical And Translational Radiation Oncology 2024, 46: 100760. PMID: 38510980, PMCID: PMC10950743, DOI: 10.1016/j.ctro.2024.100760.Peer-Reviewed Original ResearchAdapt-to-shapeStereotactic body radiation therapyIMRT plansVMAT plansTarget coverageMR-LinacPlan qualityAdapt-to-shape workflowElekta Unity MR-linacMonaco treatment planning systemSoft tissue contrastVMAT treatment plansTreatment planning systemUnity MR-linacCritical organ dosesMR-guided radiotherapyHead and neckAdapt-to-positionRadiation therapyMean doseVarian TrueBeamTrueBeam STxOAR dosesDosimetric differencesElekta UnityGuide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) ∗
Miller J, Binnicker M, Campbell S, Carroll K, Chapin K, Gonzalez M, Harrington A, Jerris R, Kehl S, Leal S, Patel R, Pritt B, Richter S, Robinson-Dunn B, Snyder J, Telford S, Theel E, Thomson R, Weinstein M, Yao J. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM) ∗. Clinical Infectious Diseases 2024, ciae104. PMID: 38442248, DOI: 10.1093/cid/ciae104.Peer-Reviewed Original ResearchInfectious Diseases Society of AmericaSoft tissue infectionsTissue infectionsTract infectionsMicrobiology laboratoryCentral nervous system infectionLower Respiratory Tract InfectionsUrinary tract infectionHead and neckInfectious Diseases SocietyNervous system infectionRespiratory tract infectionsTissue parasite infectionsUpper respiratory infectionAmerican Society for MicrobiologyProlonged turnaround timeInfectious diseasesTests to orderGenital infectionIntraabdominal infectionsBloodstream infectionsOcular infectionsDiagnosis of infectious diseasesViral syndromeJoint infectionLymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation
Kauke-Navarro M, Sadigh S, Lee C, Panayi A, Knoedler L, Knoedler S, Stoegner V, Huelsboemer L, Jamil A, Ko C, Lian C, Murphy G, Pomahac B. Lymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation. Journal Of Plastic Reconstructive & Aesthetic Surgery 2024, 91: 268-275. PMID: 38430863, DOI: 10.1016/j.bjps.2024.02.024.Peer-Reviewed Original ResearchLymph nodesVascularized composite allograftsGranzyme BDonor-derived immune cellsFacial vascularized composite allograftMedian time of presentationFacial vascularized composite allotransplantationImmunological processesGranzyme B expressionCytotoxic T cellsNecrotizing histiocytic lymphadenitisHead and neckRetrospective cohort studyTime of presentationStages of follow-upCoexistence of donorFace transplant patientsBilateral adenopathyIncreased histiocytesSuperficial lymph nodesVascularized composite allotransplantationBilateral lymphadenopathyAllograft rejectionTransplant patientsDendritic cellsClinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy
Maroongroge S, Mohamed A, Nguyen C, De la Vega J, Frank S, Garden A, Gunn B, Lee A, Mayo L, Moreno A, Morrison W, Phan J, Spiotto M, Court L, Fuller C, Rosenthal D, Netherton T. Clinical acceptability of automatically generated lymph node levels and structures of deglutition and mastication for head and neck radiation therapy. Physics And Imaging In Radiation Oncology 2024, 29: 100540. PMID: 38356692, PMCID: PMC10864833, DOI: 10.1016/j.phro.2024.100540.Peer-Reviewed Original ResearchLymph node levelsAI contoursClinical acceptanceSwallowing structuresComputed tomographyHead and neck radiotherapy patientsHead and neckMedian Dice similarity coefficientLevels I-VDice similarity coefficientRadiotherapy patientsCT scanManual contouringLymphComplex anatomyCT imagesCohortI-VPatientsChewingSimilarity coefficientAnatomyRadiotherapyHeadNode level
2023
SwinCross: Cross‐modal Swin transformer for head‐and‐neck tumor segmentation in PET/CT images
Li G, Chen J, Jang S, Gong K, Li Q. SwinCross: Cross‐modal Swin transformer for head‐and‐neck tumor segmentation in PET/CT images. Medical Physics 2023, 51: 2096-2107. PMID: 37776263, DOI: 10.1002/mp.16703.Peer-Reviewed Original ResearchConceptsCross-modal attentionDeep convolutional neural networkSemantic segmentation taskSwin TransformerFeature representationSegmentation taskAttention moduleTumor segmentationState-of-the-art transformer-based modelsMultiple resolutionsSegmentation modelModel long-range dependenciesMulti-modal feature representationCross-modal attention moduleMulti-modal input dataSelf-attention mechanismState-of-the-artTransformer-based modelsNovel segmentation modelConvolutional neural networkVision Transformer modelMulti-modal dataInter-modal correlationHead and neckTransformation model
2022
Abstract 2405: Expression of the low affinity neurotrophin receptor (p75NTR) correlates with perineural invasion in adenoid cystic carcinoma of the lacrimal gland
Moeyersoms A, Gallo R, Weiss M, Maeng M, Tse D, Pelaez D. Abstract 2405: Expression of the low affinity neurotrophin receptor (p75NTR) correlates with perineural invasion in adenoid cystic carcinoma of the lacrimal gland. Cancer Research 2022, 82: 2405-2405. DOI: 10.1158/1538-7445.am2022-2405.Peer-Reviewed Original ResearchLacrimal gland adenoid cystic carcinomaAdenoid cystic carcinomaLow-affinity neurotrophin receptorPerineural invasionAffinity neurotrophin receptorCystic carcinomaLacrimal glandPoor prognosisAmerican Association for Cancer Research annual meetingsHead and neck adenoid cystic carcinomaAnd neck adenoid cystic carcinomaLow-affinity nerve growth factor receptorNeurotrophin receptorNerve growth factor receptorPerineural invasive phenotypeMurine lacrimal glandHead and neckExpression of p75NTRGrowth factor receptorIndolent cancersIntracranial spreadRadical treatmentP75NTR expressionActivating mutationsFactor receptorA new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305.
Argiris A, Flamand Y, Savvides P, Johnson J, Li S, Forastiere A, Burtness B. A new prognostic model in patients with recurrent or metastatic head and neck cancer treated with chemotherapy: An analysis of ECOG-ACRIN E1305. Journal Of Clinical Oncology 2022, 40: 6026-6026. DOI: 10.1200/jco.2022.40.16_suppl.6026.Peer-Reviewed Original ResearchOverall survivalFirst-line treatmentMedian OSPrognostic factorsHazard ratioBone/liver metastasesRM-SCCHNFirst-lineFirst-line treatment of patientsMultivariate modelMetastatic squamous cell carcinomaPhase III randomized trialRisk factorsCancer treated with chemotherapyPlatinum-based chemotherapyECOG performance statusCooperative group trialsSquamous cell carcinomaHead and neckTumor cell differentiationTreatment of patientsPrognostic scoring modelCox proportional hazards modelsProportional hazards modelPrior radiation
2021
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck
Ferrarotto R, Amit M, Nagarajan P, Rubin M, Yuan Y, Bell D, El-Naggar A, Johnson J, Morrison W, Rosenthal D, Glisson B, Johnson F, Lu C, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis C, Weber R, Wargo J, Basu S, Duan F, Yadav S, Sharma P, Allison J, Myers J, Gross N. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research 2021, 27: 4557-4565. PMID: 34187851, PMCID: PMC8711237, DOI: 10.1158/1078-0432.ccr-21-0585.Peer-Reviewed Original ResearchConceptsCutaneous squamous cell carcinomaInflamed tumor microenvironmentSquamous cell carcinomaHead and neckCSCC-HNNeoadjuvant immunotherapyCell carcinomaTumor microenvironmentPathological responsePD-1 inhibitionCurative-intent surgeryPathological response rateBiomarkers of responseT cell clustersOS ratesNeoadjuvant treatmentPartial responseRecurrent diseaseExploratory endpointsPrimary endpointSecondary endpointsImmune biomarkersFollow-upCyTOF analysisPatients
2013
Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects
Deneve J, Turaga K, Marzban S, Puleo C, Sarnaik A, Gonzalez R, Sondak V, Zager J. Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects. The American Surgeon 2013, 79: 476-482. PMID: 23635582, PMCID: PMC4505800, DOI: 10.1177/000313481307900522.Peer-Reviewed Original ResearchMeSH KeywordsAcellular DermisAdultAgedAged, 80 and overCarcinomaCellulitisCollagenDermatofibrosarcomaFemaleHumansMaleMelanomaMiddle AgedPlastic Surgery ProceduresPostoperative ComplicationsRetrospective StudiesSkin NeoplasmsSkin TransplantationSoft Tissue NeoplasmsSurgical FlapsTreatment OutcomeWound HealingConceptsAlloDerm reconstructionInstitutional review board-approved review of patientsDefinitive reconstructionInstitutional review board-approved reviewReview of patientsHead and neckSoft tissue malignancyMedian defect sizeSoft tissue resectionSplit-thickness skin graftEarly postoperative findingsComplex surgical defectsSoft tissue defectsAdjuvant radiationPositive marginsOral antibioticsSingle-institutionClinicopathological variablesCosmetic outcomePostoperative examinationFrequent complicationPostoperative findingsMalignant defectsSurgical defectsTissue malignancy
2009
Pediatric FDG PET/CT: Physiologic Uptake, Normal Variants, and Benign Conditions1
Shammas A, Lim R, Charron M. Pediatric FDG PET/CT: Physiologic Uptake, Normal Variants, and Benign Conditions1. RadioGraphics 2009, 29: 1467-86. PMID: 19755606, DOI: 10.1148/rg.295085247.Peer-Reviewed Original ResearchConceptsPositron emission tomographyFDG uptakeBenign lesionsPhysiological uptakeIncreased (18)F-FDG uptakeFDG-PET/CT studiesPhysiological variantsHead and neckAssociated with pitfallsUrinary collecting systemPediatric oncology patientsPET/CT studiesFollow-up studyPET/computed tomographicBone marrowImprove patient treatmentOncology patientsNormal variantsPET image interpretationEmission tomographyPatient treatmentAttenuation correctionAdipose tissueBrown adipose tissueGastrointestinal tractTowards Identification of Hereditary DNA Mismatch Repair Deficiency: Sebaceous Neoplasm Warrants Routine Immunohistochemical Screening Regardless of Patient's Age or Other Clinical Characteristics
Orta L, Klimstra D, Qin J, Mecca P, Tang L, Busam K, Shia J. Towards Identification of Hereditary DNA Mismatch Repair Deficiency: Sebaceous Neoplasm Warrants Routine Immunohistochemical Screening Regardless of Patient's Age or Other Clinical Characteristics. The American Journal Of Surgical Pathology 2009, 33: 934-944. PMID: 19342947, DOI: 10.1097/pas.0b013e318199edca.Peer-Reviewed Original ResearchConceptsTumor-infiltrating lymphocytesDNA mismatch repair deficiencyPeritumoral lymphocytic responseSebaceous neoplasmsMismatch repair deficiencyDNA mismatch repair proteinsPatient ageClinical characteristicsLymphocyte responsesAbnormal expressionSebaceous adenomaSebaceous tumorsRepair deficiencyMismatch repair proteinsImmunohistochemical expression of MLH1Head and neckPositive family historyAbnormal IHC stainingExpression of DNA mismatch repair proteinsIdentical staining patternStudy tissue samplesRepair proteinsSebaceous carcinomaVisceral malignancyTumor types
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply